Nonfasting lipemia and inflammation as cardiovascular disease risks after SCI

Topics in Spinal Cord Injury Rehabilitation

Volumn 14, Issue 3, 2009, Pages 15-31

  Nash, Mark S ^a,b   Mendez, Armando J ^b,c  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Division of Endocrinology   (United States)

Author keywords

Cardiovascular diseases; Dyslipidemias; Inflammation; Postprandial period; Risk factors; Spinal cord injuries

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; ENDOTHELIN 1; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DISABLED PERSON; DYSLIPIDEMIA; ELECTROSTIMULATION THERAPY; EXERCISE; FAT INTAKE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LOW CALORY DIET; LOW FAT DIET; MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARAPLEGIA; POSTPRANDIAL STATE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPINAL CORD INJURY;

EID: 59849088760     PISSN: 10820744     EISSN: None     Source Type: Journal    
DOI: 10.1310/sci1403-15     Document Type: Review

References (160)

1. Bauman WA, Spungen AM. Coronary heart disease in individuals with spinal cord injury: Assessment of risk factors. Spinal Cord. 2008;46:466-476.
2. Groah SL, Menter RR. Long-term cardiac ischemia leading to coronary artery bypass grafting in a tetraplegic patient. Arch Phys Med Rehabil. 1998;79:1129-1132.
3. Nash MS and Mendez AJ. A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia. Arch Phys Med Rehabil. 2007;88:751-757.
4. Bauman WA, Spungen AM, Adkins RH, Kemp BJ. Metabolic and endocrine changes in persons aging with spinal cord injury. Assist Technol. 1999;11:88-96.
5. Bauman WA, Kahn NN, Grimm DR, Spungen AM. Risk factors for atherogenesis and cardiovascular autonomic function in persons with spinal cord injury. Spinal Cord. 1999;37:601-616.
6. Manns PJ, McCubbin JA, Williams DP. Fitness, inflammation, and the metabolic syndrome in men with paraplegia. Arch Phys Med Rehabil. 2005;86:1176-1181.
7. Myers J, Lee M, Kiratli J. Cardiovascular disease in spinal cord injury: An overview of prevalence, risk, evaluation, and management. Am J Phys Med Rehabil. 2007;86:142-152.
8. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
9. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-2449.
10. Mensah GA, Mokdad AH, Ford E, Narayan KM, Giles WH, Vinicor F, Deedwania PC. Obesity, metabolic syndrome, and type 2 diabetes: Emerging epidemics and their cardiovascular implications. Cardiol Clin. 2004;22:485-504.
11. Cziraky MJ. Management of dyslipidemia in patients with metabolic syndrome. J Am Pharm Assoc. 2004;44:478-488; quiz 489-490.
12. Nash MS. Exercise as a health-promoting activity following spinal cord injury. J Neurol Phys Ther. 2005;29:87-103, 106.
13. Zlotolow SP, Levy E, Bauman WA. The serum lipoprotein profile in veterans with paraplegia: The relationship to nutritional factors and body mass index. J Am Paraplegia Soc. 1992;15:158-162.
14. Cardus D, Ribas-Cardus F, McTaggart WG. Lipid profiles in spinal cord injury. Paraplegia. 1992;30:775-782.
15. Bostom AG, Toner MM, McArdle WD, Montelione T, Brown CD, Stein RA. Lipid and lipoprotein profiles relate to peak aerobic power in spinal cord injured men. Med Sci Sports Exerc. 1991;23:409-414.
16. Nash MS, Jacobs PL, Mendez AJ, Goldberg RB. Circuit resistance training improves the atherogenic lipid profiles of persons with chronic paraplegia. J Spinal Cord Med. 2001;24:2-9.
17. Bauman WA, Spungen AM, Zhong YG, Rothstein JL, Petry C, Gordon SK. Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury. Paraplegia. 1992;30:697-703.
18. Bauman WA, Adkins RH, Spungen AM, et al. Is immobilization associated with an abnormal lipoprotein profile? Observations from a diverse cohort. Spinal Cord. 1999;37:485-493.
19. Bauman WA. Endocrinology and metabolism after spinal cord injury. In: Kirshblum S, Campagnolo DI, DeLisa JA, eds. Spinal Cord Medicine. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:164-180.
20. Nash MS, Johnson BM, Jacobs PL. Combined hyperlipidemia in a single subject with tetraplegia: Ineffective risk reduction afteratorvastatin monotherapy. J Spinal Cord Med. 2004;27:484-487.
21. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
22. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation. 2008;117:743-753.
23. Heine RJ. The role of postprandial hyperglycemia and hyperlipidemia in CVD risk. Curr Diab Rep. 2006;6:1-2.
24. Cohn JS. Postprandial lipemia and remnant lipoproteins. Clin Lab Med. 2006;26:773-786.
25. Zilversmit DB. Atherogenesis: A postprandial phenomenon. Circulation. 1979;60:473-485.
26. Pastromas S, Terzi AB, Tousoulis D, Koulouris S. Postprandial lipemia: An under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol. 2008;126:3-12.
27. Paglialunga S, Cianflone K. Regulation of postprandial lipemia: An update on current trends. Appl Physiol Nutr Metab. 2007;32:61-75.
28. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J. 1998;19(Suppl A):A40-44.
29. Karpe F, Hamsten A. Postprandial lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 1995;6:123-129.
30. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
31. Karpe F, de Faire U, Mercuri M, Bond MG, Hellenius ML, Hamsten A. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclerosis. 1998;141:307-314.
32. Boquist S, Ruotolo G, Tang R, et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation. 1999;100:723-728.
33. Teno S, Uto Y, Nagashima H, Endoh Y, Iwamoto Y, Omori Y, Takizawa T. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care. 2000;23:1401-1406.
34. Nash MS, DeGroot J, Martinez-Arizala A, Mendez AJ. Evidence for an exaggerated postprandial lipemia in chronic paraplegia. J Spinal Cord Med. 2005;28:320-325.
35. Gerhart KA, Bergstrom E, Charlifue SW, Menter RR, Whiteneck GG. Long-term spinal cord injury: Functional changes over time. Arch Phys Med Rehabil. 1993;74:1030-1034.
36. Maki KC, Briones ER, Langbein WE, Inman-Felton A, Nemchausky B, Welch M, Burton J. Associations between serum lipids and indicators of adiposity in men with spinal cord injury. Paraplegia. 1995;33:102-109.
37. Levine AM, Nash MS, Green BA, Shea JD, Aronica MJ. An examination of dietary intakes and nutritional status of chronic healthy spinal cord injured individuals. Paraplegia. 1992;30:880-889.
38. Washburn RA and Figoni SF. Physical activity and chronic cardiovascular disease prevention in spinal cord injury: A comprehensive literature review. Top Spinal Cord Inj Rehabil. 1998;3:16-32.
39. Nash MS. Exercise reconditioning of the heart and peripheral circulation after spinal cord injury. Top Spinal Cord Inj Rehabil. 1997;3:1-15.
40. Duckworth WC, Solomon SS, Jallepalli P, Heckemeyer C, Finnern J, Powers A. Glucose intolerance due to insulin resistance in patients with spinal cord injuries. Diabetes. 1980;29:906-910.
41. Bauman WA, Spungen AM. Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: A model of premature aging. Metabolism. 1994;43:749-756.
42. Davies DS, McColl MA. Lifestyle risks for three disease outcomes in spinal cord injury. Clin Rehabil. 2002;16:96-108.
43. Castro MJ, Apple DF Jr, Staron RS, Campos GE, Dudley GA. Influence of complete spinal cord injury on skeletal muscle within 6 mo of injury. J Appl Physiol. 1999;86:350-358.
44. Talmadge RJ, Castro MJ, Apple DF Jr, Dudley GA. Phenotypic adaptations in human muscle fibers 6 and 24 wk after spinal cord injury. J Appl Physiol. 2002;92:147-154.
45. Lotta S, Scelsi R, Alfonsi E, Saitta A, Nicolotti D, Epifani P, Carraro U. Morphometric and neurophysiological analysis of skeletal muscle in paraplegic patients with traumatic cord lesion. Paraplegia. 1991;29:247-252.
46. Plutzky J. Inflammation in atherosclerosis and diabetes mellitus. Rev Endocr Metab Disord. 2004;5:255-259.
47. Tracy RP. Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S29-34.
48. Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol. 2000;15:416-421.
49. Yoshida M. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb. 2003;10:140-144.
50. Anderson RA, Evans ML, Ellis GR, et al. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis. 2001;154:475-483.
51. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest. 2001;108:635-636.
52. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment. Circulation. 2002;106:1211-1218.
53. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation. 2002;106:2067-2072.
54. Bae JH, Bassenge E, Kim KB, et al. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis. 2001;155:517-523.
55. Ferreira AC, Peter AA, Mendez AJ, et al. Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation. 2004;110:3599-3603.
56. Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: Clinical strategies for treating oxidant stress. Am Heart J. 2003;146:218-226.
57. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes. 2004;53:701-710.
58. Basu A, Devaraj S, Jialal I. Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol. 2006;26:995-1001.
59. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: Rationale for screening and primary prevention. Am J Cardiol. 2003;92:17K-22K.
60. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44:6-11.
61. Matos-Souza JR, Pithon KR, Ozahata TM. Carotid intima-media thickness is increased in patients with spinal cord injury independent of traditional cardiovascular risk factors. Atherosclerosis. 2009;202:29-31.
62. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. [Epub] Nov. 9, 2008.
63. Pepys MB and Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212.
64. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
65. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation. 2003;108:161-165.
66. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
67. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: Results from a large cohort study in southern Germany. Circulation. 2004;109:1349-1353.
68. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
69. Fredrikson GN, Hedblad B, Nilsson JA, Alm R, Berglund G, Nilsson J. Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. Metabolism. 2004;53:1436-1442.
70. Guerrero-Romero F and Rodriguez-Moran M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab. 2003;29:65-71.
71. Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003;166:387-394.
72. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106:2908-2912.
73. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
74. Aronson D, Sella R, Sheikh-Ahmad M, et al. The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. J Am Coll Cardiol. 2004;44:2003-2007.
75. Mojiminiyi OA, Abdella N, Moussa MA, Akanji AO, Al Mohammedi H, Zaki M. Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2002;58:37-44.
76. Niskanen L, Laaksonen DE, Nyyssonen K, et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension. 2004;44:859-865.
77. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149-154.
78. Tamakoshi K, Yatsuya H, Kondo T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord. 2003;27:443-449.
79. Grau AJ, Buggle F, Becher H, Werle E, Hacke W. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res. 1996;82:245-255.
80. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. C-reactive protein and angiographic coronary artery disease: Independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol. 2002;39:632-637.
81. Li JJ and Fang CH. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses. 2004;63:100-102.
82. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
83. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531-2534.
84. Verma S. Endothelin antagonism and insulin's vascular effects. Hypertension. 2002;40:e12-13; author reply e12-13.
85. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513-520.
86. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4:361-368.
87. Woollard KJ, Phillips DC, Griffiths HR. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol. 2002;130:256-262.
88. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA. 2002;99:13043-13048.
89. Tebo JM, Mortensen RF. Internalization and degradation of receptor bound C-reactive protein by U-937 cells: Induction of H2O2 production and tumoricidal activity. Biochim Biophys Acta. 1991;1095:210-216.
90. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S-460S.
91. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
92. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
93. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: A comprehensive appraisal. Cardiovasc Diabetol. 2006;5:4.
94. Feletou M, Vanhoutte PM. Endothelial dysfunction: A multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291:H985-1002.
95. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation. 2007;116:1832-1844.
96. Hansson GK and Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol. 2006;6:508-519.
97. Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res. 2007;101.234-247.
98. Frost F, Roach MJ, Kushner I, Schreiber P. Inflammatory C-reactive protein and cytokine levels in asymptomatic people with chronic spinal cord injury. Arch Phys Med Rehabil. 2005;86:312-317.
99. Lang CH, Frost RA. Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection. Curr Opin Clin Nutr Metab Care. 2002;5:271-279.
100. Milias GA, Nomikos T, Fragopoulou E, Athanasopoulos S, Antonopoulou S. Effects of eccentric exercise-induced muscle injury on blood levels of platelet activating factor (PAF) and other inflammatory markers. Eur J Appl Physiol. 2005;95:504-513.
101. Banovac K, Sherman AL, Estores IM, Banovac F. Prevention and treatment of heterotopic ossification after spinal cord injury. J Spinal Cord Med. 2004;27:376-382.
102. Estrores IM, Harrington A, Banovac K. C-reactive protein and erythrocyte sedimentation rate in patients with heterotopic ossification after spinal cord injury. J Spinal Cord Med. 2004;27:434-437.
103. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
104. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-428.
105. Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Clinical use of inflammatory markers in patients with cardiovascular diseases: A background paper. Circulation. 2004;110:e560-567.
106. Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis. 2000;9:37-41.
107. Lee MY, Myers J, Hayes A, Madan S, Froelicher VF, Perkash I, Kiratli BJ. C-reactive protein, metabolic syndrome, and insulin resistance in individuals with spinal cord injury. J Spinal Cord Med. 2005;28:20-25.
108. Wang TD, Wang YH, Huang TS, Su TC, Pan SL, Chen SY. Circulating levels of markers of inflammation and endothelial activation are increased in men with chronic spinal cord injury. J Formos Med Assoc. 2007;106:919-928.
109. Liang H, Mojtahedi MC, Chen D, Braunschweig CL. Elevated C-reactive protein associated with decreased high-density lipoprotein cholesterol in men with spinal cord injury. Arch Phys Med Rehabil. 2008;89:36-41.
110. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
111. Morse LR, Stolzmann K, Nguyen HP, Jain NB, Zayac C, Gagnon DR, Tun CG, Garshick E. Association between mobility mode and C-reactive protein levels in men with chronic spinal cord injury. Arch Phys Med Rehabil. 2008;89:726-731.
112. Nash MS, SL Gintel, AJ Mendez, LF Hamm, JE Lewis, SL Groah. Elevated CRP and vascular disease after SCI: Inflammatory epiphenomenon or pathologic agent? J Spinal Cord Med. 2006;29(3):252.
113. Cirillo P, Golino P, Calabro P, et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res. 2005;68:47-55.
114. Bledsoe SL, Barr JC, Fitzgerald RT, Brown AT, Faas FH, Eidt JF, Moursi MM. Pravastatin and clopidogrel combined inhibit intimal hyperplasia in a rat carotid endarterectomy model. Vasc Endovascular Surg. 2006;40:49-57.
115. Cortes B, Nunez I, Cofan M, et al E. Acute effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial function. J Am Coll Cardiol. 2006;48:1666-1671.
116. Lairon D, Play B, Jourdheuil-Rahmani D. Digestible and indigestible carbohydrates: Interactions with postprandial lipid metabolism. J Nutr Biochem. 2007;18:217-227.
117. Zhang JQ, Ji LL, Fretwell VS, Nunez G. Effect of exercise on postprandial lipemia in men with hypertriglyceridemia. Eur J Appl Physiol. 2006;98:575-582.
118. Petitt DS, Cureton KJ. Effects of prior exercise on postprandial lipemia: A quantitative review. Metabolism. 2003;52:418-424.
119. Karpe F. Postprandial lipemia - effect of lipid-lowering drugs. Atheroscler Suppl. 2002;3:41-46.
120. Yagi T, Yamauchi K, Kuwano S. The synergistic purgative action of aloe-emodin anthrone and rhein anthrone in mice: Synergism in large intestinal propulsion and water secretion. J Pharm Pharmacol. 1997;49:22-25.
121. Shin J, Edelberg JE, Hong MK. Vulnerable atherosclerotic plaque: Clinical implications. Curr Vasc Pharmacol. 2003;1:183-204.
122. Stone NJ. Diet, lipids, and coronary heart disease. Endocrinol Metab Clin North Am. 1990;19:321-344.
123. Wilson MM, Thomas DR. Dietary factors in atherogenesis. Curr Atheroscler Rep. 2003;5:324-330.
124. Sanders TA. Dietary fat and postprandial lipids. Curr Atheroscler Rep. 2003;5:445-451.
125. Griffin MD, Sanders TA, Davies IG, et a I. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: The OPTILIP Study. Am J Clin Nutr. 2006;84:1290-1298.
126. Berry SE, Miller GJ, Sanders TA. The solid fat content of stearic acid-rich fats determines their postprandial effects. Am J Clin Nutr. 2007;85:1486-1494.
127. Smith BK, Sun GY, Donahue OM, Thomas TR. Exercise plus n-3 fatty acids: Additive effect on postprandial lipemia. Metabolism. 2004;53:1365-1371.
128. Hardman AE. Physical activity, obesity and blood lipids. Int J Obes Relat Metab Disord. 1999;23(Suppl 3):S64-71.
129. Katsanos CS. Prescribing aerobic exercise for the regulation of postprandial lipid metabolism: Current research and recommendations. Sports Med. 2006;36:547-560.
130. Parhofer KG, Barrett PH, Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab. 2000;85:4224-4230.
131. van Oostrom AJ, van Wijk J, Cabezas MC. Lipaemia, inflammation and atherosclerosis: Novel opportunities in the understanding and treatment of atherosclerosis. Drugs. 2004;64(Suppl 2):19-41.
132. Gill JM, Frayn KN, Wootton SA, Miller GJ, Hardman AE. Effects of prior moderate exercise on exogenous and endogenous lipid metabolism and plasma factor VII activity. Clin Sci (Lond). 2001;100:517-527.
133. Tsetsonis NV, Hardman AE, Mastana SS. Acute effects of exercise on postprandial lipemia: A comparative study in trained and untrained middle-aged women. Am J Clin Nutr. 1997;65:525-533.
134. Hardman AE, Herd SL. Exercise and postprandial lipid metabolism. Proc Nutr Soc. 1998;57:63-72.
135. Koutsari C, Hardman AE. Exercise prevents the augmentation of postprandial lipaemia attributable to a low-fat high-carbohydrate diet. Br J Nutr. 2001;86:197-205.
136. Murphy MH, Nevill AM, Hardman AE. Different patterns of brisk walking are equally effective in decreasing postprandial lipaemia. Int J Obes Relat Metab Disord. 2000;24:1303-1309.
137. Herd SL, Lawrence JE, Malkova D, Murphy MH, Mastana S, Hardman AE. Postprandial lipemia in young men and women of contrasting training status. J Appl Physiol. 2000;89:2049-2056.
138. Hardman AE. The influence of exercise on postprandial triacylglycerol metabolism. Atherosclerosis. 1998;141(Suppl 1):S93-100.
139. Malkova D, Hardman AE, Bowness RJ, Macdonald IA. The reduction in postprandial lipemia after exercise is independent of the relative contributions of fat and carbohydrate to energy metabolism during exercise. Metabolism. 1999;48:245-251.
140. Herd SL, Kiens B, Boobis LH, Hardman AE. Moderate exercise, postprandial lipemia, and skeletal muscle lipoprotein lipase activity. Metabolism. 2001;50:756-762.
141. Tsetsonis NV and Hardman AE. Reduction in postprandial lipemia after walking: Influence of exercise intensity. Med Sci Sports Exerc. 1996;28:1235-1242.
142. Petitt DS, Arngrimsson SA, Cureton KJ. Effect of resistance exercise on postprandial lipemia. J Appl Physiol. 2003;94:694-700.
143. Shannon KA, Shannon RM, Clore JN, Gennings C, Warren BJ, Potteiger JA. Resistance exercise and postprandial lipemia: The dose effect of differing volumes of acute resistance exercise bouts. Metabolism. 2005;54:756-763.
144. Herd SL, Hardman AE, Boobis LH, Cairns CJ. The effect of 13 weeks of running training followed by 9 d of detraining on postprandial lipaemia. Br J Nutr. 1998;80:57-66.
145. Hamilton MT, Hamilton DG, Zderic TW. Exercise physiology versus inactivity physiology: An essential concept for understanding lipoprotein lipase regulation. Exerc Sport Sci Rev. 2004;32:161-166.
146. Grandjean PW, Crouse SF, Rohack JJ. Influence of cholesterol status on blood lipid and lipoprotein enzyme responses to aerobic exercise. J Appl Physiol. 2000;89:472-480.
147. Weise SD, Grandjean PW, Rohack JJ, Womack JW, Crouse SF. Acute changes in blood lipids and enzymes in postmenopausal women after exercise. J Appl Physiol. 2005;99:609-615.
148. Magkos F, Wright DC, Patterson BW, Mohammed BS, Mittendorfer B. Lipid metabolism response to a single, prolonged bout of endurance exercise in healthy young men. Am J Physiol Endocrinol Metab. 2006;290:E355-362.
149. Paton CM, Brandauer J, Weiss EP, Brown MD, Ivey FM, Roth SM, Hagberg JM. Hemostatic response to postprandial lipemia before and after exercise training . J Appl Physiol. 2006;101:316-321.
150. Zhang JQ, Ji LL, Nunez G, Feathers S, Hart CL, Yao WX. Effect of exercise timing on postprandial lipemia in hypertriglyceridemia men. Can J Appl Physiol. 2004;29:590-603.
151. Samoilenko Elu, Naumov VG, Tvorogova MG, Ezhov MV, Sergienko IV, Kukharchuk VV. [Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease]. Kardiologiia. 2007;47:4-8.
152. Kolovou GD, Anagnostopoulou KK, Salpea KD, Daskalopoulou SS, Mikhailidis DP. The effect of statins on postprandial lipemia. Curr Drug Targets. 2007;8:551-560.
153. Plaisance EP, Mestek ML, Mahurin AJ, Taylor JK, Moncada-Jimenez J, Grandjean PW. Postprandial triglyceride responses to aerobic exercise and extended-release niacin. Am J Clin Nutr. 2008;88:30-37.
154. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007;30:1945-1951.
155. Rosenson RS, Huskin AL, Wolff DA, Helenowski IB, Rademaker AW. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis. 2008;198:381-388.
156. Kolovou GD, Kostakou PM, Anagnostopoulou KK, Cokkinos DV. Therapeutic effects of fibrates in postprandial lipemia. Am J Cardiovasc Drugs. 2008;8:243-255.
157. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism. 2008;57:380-386.
158. Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. Ann Clin Lab Sci. 2007;37:158-166.
159. Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelstiel CD, Karas RH. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006;98:743-745.
160. Ng DS. Treating low HDL-from bench to bedside. Clin Biochem. 2004;37:649-659.